This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

T-cell Minimal Residual Disease (MRD) Evaluation Using Flow Cytometric Analysis

This study has been completed.
Information provided by:
Stanford University Identifier:
First received: February 26, 2010
Last updated: March 1, 2010
Last verified: February 2010
To determine if MRD (minimal residual disease) can be found in the blood (only) as opposed to bone marrow in children with ALL (acute lymphoblastic leukemia).

Condition Intervention
Leukemia, Lymphocytic, Acute Procedure: bone marrow aspiration Procedure: peripheral blood sampling

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: T-cell MRD Evaluation Using Flow Cytometric Analysis

Resource links provided by NLM:

Further study details as provided by Stanford University:

Biospecimen Retention:   Samples With DNA
blood and bone marrow

Estimated Enrollment: 15
Study Start Date: November 2002
Study Completion Date: October 2007
Primary Completion Date: October 2007 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   up to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
children with newly diagnosed T-cell ALL

Inclusion Criteria:

  • Children with newly diagnosed T-cell ALL
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01078337

United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Principal Investigator: Gary V Dahl Stanford University
  More Information

Responsible Party: Gary V Dahl, Stanford University School of Medicine Identifier: NCT01078337     History of Changes
Other Study ID Numbers: SU-11022007-790
Study First Received: February 26, 2010
Last Updated: March 1, 2010

Additional relevant MeSH terms:
Leukemia, Lymphoid
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Neoplasm, Residual
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Neoplastic Processes
Pathologic Processes processed this record on August 21, 2017